AAPL315.32-0.90 (-0.28%) ▼|ABBV248.08-1.83 (-0.73%) ▼|ABT93.93-0.47 (-0.50%) ▼|ACN135.23-3.83 (-2.75%) ▼|ADBE223.64+0.99 (+0.44%) ▲|AMAT602.50+13.84 (+2.35%) ▲|AMD557.89+11.17 (+2.04%) ▲|AMGN363.39-0.23 (-0.06%) ▼|AMT168.59+3.59 (+2.18%) ▲|AMZN245.34-1.70 (-0.69%) ▼|AVGO399.97-1.14 (-0.28%) ▼|AXP350.58+3.86 (+1.11%) ▲|BA222.28-0.83 (-0.37%) ▼|BAC59.67+0.42 (+0.71%) ▲|BKNG178.39+2.87 (+1.64%) ▲|BLK1,036.11+16.43 (+1.61%) ▲|BMY57.58-0.36 (-0.62%) ▼|BNY151.92-0.34 (-0.22%) ▼|BRK-B493.71-1.74 (-0.35%) ▼|C140.79+1.22 (+0.87%) ▲|CAT952.41+14.02 (+1.49%) ▲|CL92.24+1.23 (+1.35%) ▲|CMCSA23.57+0.23 (+0.96%) ▲|COF201.52+1.42 (+0.71%) ▲|COP109.04+1.02 (+0.94%) ▲|COST916.25+3.28 (+0.36%) ▲|CRM163.32+0.82 (+0.50%) ▲|CSCO121.31+3.00 (+2.54%) ▲|CVS104.15+1.34 (+1.30%) ▲|CVX176.40+2.35 (+1.35%) ▲|DE586.86-6.04 (-1.02%) ▼|DHR199.05+3.07 (+1.57%) ▲|DIS95.62-0.55 (-0.57%) ▼|DUK125.48+0.22 (+0.18%) ▲|EMR138.88+1.08 (+0.78%) ▲|FDX314.69+3.85 (+1.24%) ▲|GD375.06+0.46 (+0.12%) ▲|GE359.27+0.23 (+0.06%) ▲|GEV1,091.57+16.31 (+1.52%) ▲|GILD129.83-5.01 (-3.72%) ▼|GM77.85+1.20 (+1.57%) ▲|GOOG355.03-1.21 (-0.34%) ▼|GOOGL357.18-1.71 (-0.48%) ▼|GS1,055.18-0.79 (-0.07%) ▼|HD343.30+4.57 (+1.35%) ▲|HON226.42+3.00 (+1.34%) ▲|IBM287.56-7.74 (-2.62%) ▼|INTC109.84-2.70 (-2.40%) ▼|INTU274.96+1.58 (+0.58%) ▲|ISRG406.78-4.77 (-1.16%) ▼|JNJ256.98-2.12 (-0.82%) ▼|JPM336.47+1.00 (+0.30%) ▲|KO83.49+0.86 (+1.04%) ▲|LIN529.79+4.23 (+0.80%) ▲|LLY1,188.58-28.37 (-2.33%) ▼|LMT523.22+4.96 (+0.96%) ▲|LOW211.63-1.37 (-0.64%) ▼|LRCX350.33-2.84 (-0.80%) ▼|MA526.74+3.54 (+0.68%) ▲|MCD274.60-1.89 (-0.68%) ▼|MDLZ58.83+0.53 (+0.91%) ▲|MDT83.87+1.48 (+1.80%) ▲|META669.21+37.73 (+5.97%) ▲|MMM157.52+2.18 (+1.40%) ▲|MO71.79+0.20 (+0.28%) ▲|MRK123.54-1.53 (-1.22%) ▼|MS222.28+0.15 (+0.07%) ▲|MSFT385.10+0.74 (+0.19%) ▲|MU979.30-12.34 (-1.24%) ▼|NEE87.96+0.86 (+0.99%) ▲|NFLX73.37-2.10 (-2.78%) ▼|NKE44.37+1.59 (+3.72%) ▲|NOW107.71-1.13 (-1.04%) ▼|NVDA210.96+8.18 (+4.03%) ▲|ORCL140.64-3.08 (-2.14%) ▼|PEP137.38-0.48 (-0.35%) ▼|PFE24.17-0.08 (-0.33%) ▼|PG147.04+0.19 (+0.13%) ▲|PLTR126.79-2.25 (-1.74%) ▼|PM181.62+0.45 (+0.25%) ▲|QCOM189.16-1.95 (-1.02%) ▼|RTX195.93+0.73 (+0.37%) ▲|SBUX106.01-0.40 (-0.38%) ▼|SCHW103.12+1.21 (+1.19%) ▲|SO95.61+0.44 (+0.46%) ▲|SPG218.77-0.94 (-0.43%) ▼|T21.13+0.37 (+1.77%) ▲|TMO527.05+2.34 (+0.45%) ▲|TMUS187.61+6.13 (+3.38%) ▲|TSLA407.76+1.21 (+0.30%) ▲|TXN311.46+2.93 (+0.95%) ▲|UBER74.54+0.19 (+0.26%) ▲|UNH424.62-7.06 (-1.64%) ▼|UNP286.96+1.92 (+0.67%) ▲|UPS112.47+1.73 (+1.56%) ▲|USB62.41+0.51 (+0.82%) ▲|V348.97+0.77 (+0.22%) ▲|VZ42.12+0.59 (+1.41%) ▲|WFC87.16+0.25 (+0.29%) ▲|WMT113.90+1.69 (+1.51%) ▲|XOM138.88+1.42 (+1.03%) ▲|AAPL315.32-0.90 (-0.28%) ▼|ABBV248.08-1.83 (-0.73%) ▼|ABT93.93-0.47 (-0.50%) ▼|ACN135.23-3.83 (-2.75%) ▼|ADBE223.64+0.99 (+0.44%) ▲|AMAT602.50+13.84 (+2.35%) ▲|AMD557.89+11.17 (+2.04%) ▲|AMGN363.39-0.23 (-0.06%) ▼|AMT168.59+3.59 (+2.18%) ▲|AMZN245.34-1.70 (-0.69%) ▼|AVGO399.97-1.14 (-0.28%) ▼|AXP350.58+3.86 (+1.11%) ▲|BA222.28-0.83 (-0.37%) ▼|BAC59.67+0.42 (+0.71%) ▲|BKNG178.39+2.87 (+1.64%) ▲|BLK1,036.11+16.43 (+1.61%) ▲|BMY57.58-0.36 (-0.62%) ▼|BNY151.92-0.34 (-0.22%) ▼|BRK-B493.71-1.74 (-0.35%) ▼|C140.79+1.22 (+0.87%) ▲|CAT952.41+14.02 (+1.49%) ▲|CL92.24+1.23 (+1.35%) ▲|CMCSA23.57+0.23 (+0.96%) ▲|COF201.52+1.42 (+0.71%) ▲|COP109.04+1.02 (+0.94%) ▲|COST916.25+3.28 (+0.36%) ▲|CRM163.32+0.82 (+0.50%) ▲|CSCO121.31+3.00 (+2.54%) ▲|CVS104.15+1.34 (+1.30%) ▲|CVX176.40+2.35 (+1.35%) ▲|DE586.86-6.04 (-1.02%) ▼|DHR199.05+3.07 (+1.57%) ▲|DIS95.62-0.55 (-0.57%) ▼|DUK125.48+0.22 (+0.18%) ▲|EMR138.88+1.08 (+0.78%) ▲|FDX314.69+3.85 (+1.24%) ▲|GD375.06+0.46 (+0.12%) ▲|GE359.27+0.23 (+0.06%) ▲|GEV1,091.57+16.31 (+1.52%) ▲|GILD129.83-5.01 (-3.72%) ▼|GM77.85+1.20 (+1.57%) ▲|GOOG355.03-1.21 (-0.34%) ▼|GOOGL357.18-1.71 (-0.48%) ▼|GS1,055.18-0.79 (-0.07%) ▼|HD343.30+4.57 (+1.35%) ▲|HON226.42+3.00 (+1.34%) ▲|IBM287.56-7.74 (-2.62%) ▼|INTC109.84-2.70 (-2.40%) ▼|INTU274.96+1.58 (+0.58%) ▲|ISRG406.78-4.77 (-1.16%) ▼|JNJ256.98-2.12 (-0.82%) ▼|JPM336.47+1.00 (+0.30%) ▲|KO83.49+0.86 (+1.04%) ▲|LIN529.79+4.23 (+0.80%) ▲|LLY1,188.58-28.37 (-2.33%) ▼|LMT523.22+4.96 (+0.96%) ▲|LOW211.63-1.37 (-0.64%) ▼|LRCX350.33-2.84 (-0.80%) ▼|MA526.74+3.54 (+0.68%) ▲|MCD274.60-1.89 (-0.68%) ▼|MDLZ58.83+0.53 (+0.91%) ▲|MDT83.87+1.48 (+1.80%) ▲|META669.21+37.73 (+5.97%) ▲|MMM157.52+2.18 (+1.40%) ▲|MO71.79+0.20 (+0.28%) ▲|MRK123.54-1.53 (-1.22%) ▼|MS222.28+0.15 (+0.07%) ▲|MSFT385.10+0.74 (+0.19%) ▲|MU979.30-12.34 (-1.24%) ▼|NEE87.96+0.86 (+0.99%) ▲|NFLX73.37-2.10 (-2.78%) ▼|NKE44.37+1.59 (+3.72%) ▲|NOW107.71-1.13 (-1.04%) ▼|NVDA210.96+8.18 (+4.03%) ▲|ORCL140.64-3.08 (-2.14%) ▼|PEP137.38-0.48 (-0.35%) ▼|PFE24.17-0.08 (-0.33%) ▼|PG147.04+0.19 (+0.13%) ▲|PLTR126.79-2.25 (-1.74%) ▼|PM181.62+0.45 (+0.25%) ▲|QCOM189.16-1.95 (-1.02%) ▼|RTX195.93+0.73 (+0.37%) ▲|SBUX106.01-0.40 (-0.38%) ▼|SCHW103.12+1.21 (+1.19%) ▲|SO95.61+0.44 (+0.46%) ▲|SPG218.77-0.94 (-0.43%) ▼|T21.13+0.37 (+1.77%) ▲|TMO527.05+2.34 (+0.45%) ▲|TMUS187.61+6.13 (+3.38%) ▲|TSLA407.76+1.21 (+0.30%) ▲|TXN311.46+2.93 (+0.95%) ▲|UBER74.54+0.19 (+0.26%) ▲|UNH424.62-7.06 (-1.64%) ▼|UNP286.96+1.92 (+0.67%) ▲|UPS112.47+1.73 (+1.56%) ▲|USB62.41+0.51 (+0.82%) ▲|V348.97+0.77 (+0.22%) ▲|VZ42.12+0.59 (+1.41%) ▲|WFC87.16+0.25 (+0.29%) ▲|WMT113.90+1.69 (+1.51%) ▲|XOM138.88+1.42 (+1.03%) ▲|
24.4 C
New York
Saturday, July 11, 2026

Tag: investor

newssourceFORcompanyinformationcontent1releasesmarket

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4...

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints

Napco (NSSC) Under Scrutiny: Investor Suit and Sales Slump Shake Investor Confidence – Hagens Berman

NSSC Investors with Losses Encouraged to Contact Hagens Berman Before June 24th Deadline in Securities Class Action 
NSSC Investors with Losses Encouraged to Contact Hagens Berman Before June 24th Deadline in Securities Class Action

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy...

CAMBRIDGE, Mass., June 15, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced three-year follow-up data from the Phase 1 portion of the ongoing Phase 1/2 study in patients with HAE after receiving a single dose of lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002). Results were shared in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, held June 13-16 in Glasgow, United Kingdom.

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of DoubleVerify

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In DoubleVerify To Contact Him Directly To...

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Fortrea Holdings

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Fortrea To Contact Him Directly To...

Scatec reaches financial close for the 1.1GW solar + 100MW/200MWh BESS Obelisk project

Oslo/Cairo, 15 June 2025: Scatec ASA has reached financial close for the “Obelisk” hybrid solar and battery storage project in Egypt.

Backblaze Investor News: If You Have Suffered Losses in Backblaze, Inc. (NASDAQ: BLZE), You Are Encouraged to Contact The Rosen Law Firm About Your...

NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Backblaze, Inc. (NASDAQ: BLZE) resulting from allegations that Backblaze may have issued materially misleading business information to the investing public.

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for...

Media Release

COPENHAGEN, Denmark; June 15, 2025

XRP News: Vaultro Finance Presale on XRP ledger Skyrockets Past 50%, As Investors Race to Own $VLT Token

SINGAPORE , June 15, 2025 (GLOBE NEWSWIRE) -- Vaultro Finance has just announced a landmark achievement in its public sale of the native utility token VLT. The $VLT presale Round has now achieved a 50% sale milestone, marking a pivotal moment in the project’s journey and sending a clear signal that investor demand is surging. Achieving half of the targeted hardcap in rapid fashion underscores the market’s enthusiasm for Vaultro’s revolutionary approach to decentralized index fund investing on the XRP Ledger.

Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA Data signal...

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in non-ambulatory patients

Basel, 15 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new dosing restrictions, effective immediately, for ELEVIDYS™ (delandistrogene moxeparvovec), for non-ambulatory Duchenne muscular dystrophy (DMD) patients, irrespective of age, in both clinical and commercial settings. In the commercial setting, non-ambulatory patients should no longer receive Elevidys. In the clinical trial setting, enrolment and dosing of non-ambulatory patients will be immediately paused until additional risk mitigation measures (e.g. immune modulatory treatment) are implemented in the study protocol. Health authorities, investigators and physicians are being informed so that patient care can be quickly adjusted.

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages PepGen Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PEPG

NEW YORK, June 14, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of PepGen Inc. (NASDAQ: PEPG) between March 7, 2024 and March 3, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 8, 2025.

Trump’s Steel Tariffs: Because Who Needs Affordable Appliances Anyway?

Ah, the Commerce Department strikes again, delivering yet another masterstroke in their ongoing saga of "How to Make Everything More Expensive for American Households."...

Nimanode Surpasses Crypto Presales, Eyes 10X Growth Post-Launch as Major Investors Flock to the XRP DeFi Landscape

LEEDS, United Kingdom, June 14, 2025 (GLOBE NEWSWIRE) -- Nimanode, the first no-code AI agent platform built natively on the XRP Ledger (XRPL), is gaining momentum with its ongoing $NMA token presale.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsInvestor

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers